[D-Ala2]-GRF (1-29) amide (human)

TECHNICAL SPECIFICATIONS

1.MECHANISM OF ACTION

This analog acts as a potent agonist for the Growth Hormone-Releasing Hormone Receptor (GHRHR) on pituitary somatotroph cells. The key D-Ala2 substitution prevents the rapid inactivation by DPP-IV that cleaves the native peptide after its N-terminal alanine. This dramatically increases its plasma half-life and bioavailability. Upon binding to the Gs-protein coupled GHRHR, it activates adenylate cyclase, leading to a pronounced increase in intracellular cyclic adenosine monophosphate (cAMP) levels. 

2.PRODUCT INDICATIONS

Growth Hormone Research: Investigating the physiology and pharmacology of GH secretion using a stable, potent GHRH agonist in vitro(pituitary cell cultures) and in vivo(animal models).

• Metabolic & Aging Studies: Exploring the effects of sustained GH elevation on body composition, glucose/lipid metabolism, and age-related physiological decline.

• Peptide Stability & SAR Studies: Serving as a prime example of how a single D-amino acid substitution can confer profound metabolic stability, useful for structure-activity relationship (SAR) analyses.

• Drug Discovery: Acting as a benchmark compound or a starting scaffold for developing novel, long-acting growth hormone secretagogues or GHRH analogs.

• Diagnostic Tool Development: Used in research to develop and optimize in vitrobioassays for assessing GHRH activity or pituitary somatotroph function.

• Comparative Efficacy Studies: Comparing the pharmacokinetics and pharmacodynamics of different stabilized GHRH analogs.

3.CLINICAL EFFICACY OF PRODUCT

• Direct Therapeutic Link: This specific analog is the active pharmaceutical ingredient in Tesamorelin (formerly known as TH9507), an FDA-approved drug (Egrifta®) for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.

• Proven Clinical Efficacy: As Tesamorelin, it has demonstrated significant efficacy in multiple clinical trials, reducing visceral adipose tissue, improving lipid profiles, and alleviating other metabolic disturbances in its indicated patient population.

• Research Foundation: Preclinical studies with this analog validated the concept that DPP-IV resistance leads to sustained GH release with a favorable pulsatile profile, forming the rationale for its clinical development.

• Current Status: While the research-grade peptide is not a drug itself, it is chemically identical to the core structure of an important therapeutic agent, making it a highly relevant compound for mechanistic and translational research.

  

4.DELIVERY & SHIPPING


We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods 
Main Method: International Air Freight


We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.